Discover and read the best of Twitter Threads about #MASTERDAPT
Most recents (2)
Follow this #CardioTwitter #Thread
to get an overview of ALL
🚨#ESCcongress #HotLineSessions🚨
Including:
➡️14 #OnePager #CongressCards
➡️Links to on-demand stream
➡️Jorunal weblinks
➡️Hashtag of the author/presenter
PART 2 ⬇️
to get an overview of ALL
🚨#ESCcongress #HotLineSessions🚨
Including:
➡️14 #OnePager #CongressCards
➡️Links to on-demand stream
➡️Jorunal weblinks
➡️Hashtag of the author/presenter
PART 2 ⬇️
6.1/ #eBRAVE-AF - Smartphone-based #AF screening.
📕🔗: nature.com/articles/s4159…
On-demand ESC 📺: bit.ly/3Qc6SYp
#ESCcongress
📕🔗: nature.com/articles/s4159…
On-demand ESC 📺: bit.ly/3Qc6SYp
#ESCcongress
#MASTERDAPT is out in @NEJM, short vs standard DAPT in high bleeding risk patients. Will be the most important DAPT Study we see this year. Much respect for the authors. Here’s are some quick thoughts (thread):
- high risk patients (1/3 NSTEMI, 11% STEMI, complex long lesions)
- high risk patients (1/3 NSTEMI, 11% STEMI, complex long lesions)
- OAC patients standard regimen has at least 3 months and sometimes longer of triple therapy. OAC short regimen got 1 month triple and stopped all antiplt therapy by 6 months.
- non OAC stratum majority of short regimen went to P2Y12 monotherapy with clopidogrel at 1 month.
- non OAC stratum majority of short regimen went to P2Y12 monotherapy with clopidogrel at 1 month.
Per protocol non inferiority test for combined NACE endpoint, then combined MACE endpoint, then ITT superiority test for safety (BARC 2-5 bleeding).
Major results are below. Short DAPT was non inferior for NACE and MACE, superior for bleeding.
Major results are below. Short DAPT was non inferior for NACE and MACE, superior for bleeding.
